Editorial independence

We do not sell peptides. We do not run a clinic. We do not accept payment in exchange for editorial coverage — ever. This is not aspirational, it is structural: the moment we became a shopfront, we would stop being useful.

We do generate revenue from a disclosed partner shop offer. That partnership does not influence our writing, evidence grades, or which compounds we cover.

How we research

Peptide Data is compiled with the help of an automated research agent. For each compound the agent surveys the published literature — PubMed, MHRA classifications, and clinical-trial registries — and drafts a profile graded against the evidence base below. Every draft is then read and signed off by a human editorial lead before it goes live. The agent handles the volume; the editor owns the judgement.

This is a research reference, not a prescriber. The compounds covered here are studied in preclinical and published research and are not licensed medicines in the UK. Nothing on this site is an instruction to self-administer.

How we grade evidence

Every compound profile carries one of four evidence grades, applied consistently:

  • Strong   Multiple high-quality randomised controlled trials in humans, with consistent and clinically meaningful results.
  • Moderate   Either consistent animal evidence plus limited human data, or single-trial human evidence awaiting replication.
  • Limited   Mechanistic plausibility and animal data only, or single small uncontrolled human studies.
  • Anecdotal   Practitioner reports and forum-derived information only. No formal evidence base.

Our regulatory framing

Peptide Data is written for a UK audience. We frame everything in current UK law and MHRA guidance. Where US references would discuss FDA scheduling or DEA classification, we discuss the Medicines Act, the Human Medicines Regulations 2012, and the Misuse of Drugs Act 1971. Research peptides are not licensed medicines in the UK and are not for human consumption. We say this once, clearly, and move on.

Contact

Editorial corrections, partnership enquiries, or general feedback: hello@hello.peptide-data.com. We respond to every email, though sometimes slowly.